Log in to save to my catalogue

Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postm...

Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postm...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2232985118

Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study

About this item

Full title

Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study

Publisher

New York: Springer US

Journal title

Breast cancer research and treatment, 2019-08, Vol.177 (1), p.115-125

Language

English

Formats

Publication information

Publisher

New York: Springer US

More information

Scope and Contents

Contents

Purpose
GEICAM/2006–10 compared anastrozole (A) versus fulvestrant plus anastrozole (A + F) to test the hypothesis of whether a complete oestrogen blockade is superior to aromatase inhibitors alone in breast cancer patients receiving hormone adjuvant therapy.
Methods
Multicenter, open label, phase III study. HR+/HER2− EBC postmenopausal pa...

Alternative Titles

Full title

Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2232985118

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2232985118

Other Identifiers

ISSN

0167-6806

E-ISSN

1573-7217

DOI

10.1007/s10549-019-05296-8

How to access this item